( MENAFN - Investor Brand Network) Longeveron (NASDAQ: LGVN) is a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions. The company today announced the launch of its contract development and manufacturing business at its 15,000-square-foot, state-of-the-art Good Manufacturing Practice (“GMP”) facility. In addition, the company announced the initiation of work under its first manufacturing services contract with Secretome Therapeutics , a biotechnology company developing first-in-class therapeutics from neonatal mesenchymal stem cells (“nMSC”).
“We are delighted to partner with Secretome Therapeutics to advance their portfolio of therapeutics in this, our first contract manufacturing agreement in a new, revenue generating business line,” said Longeveron CEO Wa'el Hashad.“With cellular therapy manufacturing expertise and capabilities in high demand, and Longeveron's strength in both, we see a significant opportunity to employ currently unused capacity in our state-of-the-art GMP facility. We have assembled a team of experts and proprietary technologies that enable us to take a systematic approach to rapidly develop improved cell therapies.
Longeveron's manufacturing expertise, capabilities and facility provide other pharmaceutical organizations the ability to advance their development programs without building their own manufacturing facility. We believe this contract manu.
